CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, announced today that company scientists made presentations at two premier scientific conferences. These presentations highlighted progress with the Companys lead programs in cystic fibrosis (CF) and Parkinsons disease (PD) and demonstrated the potential of its differentiated approach to developing disease modifying therapeutics.

At the North American Cystic Fibrosis Conference, we presented data that show how our Proteostasis Network drug discovery platform can identify proteostasis regulators that function as correctors of F508 CFTR, the most common genetic mutation leading to CF. Our data at the Society for Neuroscience Annual Meeting show how the modulation of proteasome activation through the inhibition of Usp14, a deubiquitinase enzyme, stimulates the degradation of -synuclein, a misfolding- and aggregation-prone protein that can accumulate in the brains of PD patients, commented Peter H. Reinhart, Ph.D., President and Chief Scientific Officer of Proteostasis Therapeutics.We are planning to begin clinical trials for both programs in 2014 and are very encouraged by the data we have generated to date.

About Proteostasis Therapeutics

Proteostasis Therapeutics is developing disease-modifying therapeutics for orphan and neurodegenerative diseases. The Companys lead programs in cystic fibrosis (CF) and protein aggregation disorders such as Parkinsons disease (PD) modulate protein chaperone and proteasomal degradation pathways within the cell. These pathways are part of the cellular quality control machinery, called the protein homeostasis network or Proteostasis Network (PN) that regulates protein folding, trafficking, and clearance. By enhancing the function and capacity of the PN, the Companys product candidates correct for imbalances in the PN resulting from the cumulative effects of disease, genetic mutations, environmental factors, and aging. For more information, please visit the Companys website at http://www.proteostasis.com.

Go here to read the rest:
Proteostasis Therapeutics Presents Data at Two Scientific Conferences for Lead Programs in Cystic Fibrosis and ...